JP2018502100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502100A5 JP2018502100A5 JP2017534365A JP2017534365A JP2018502100A5 JP 2018502100 A5 JP2018502100 A5 JP 2018502100A5 JP 2017534365 A JP2017534365 A JP 2017534365A JP 2017534365 A JP2017534365 A JP 2017534365A JP 2018502100 A5 JP2018502100 A5 JP 2018502100A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- pharmaceutical composition
- ohvitd3
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 150000003704 vitamin D3 derivatives Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 2
- 235000005282 vitamin D3 Nutrition 0.000 claims 2
- 239000011647 vitamin D3 Substances 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 229940021056 vitamin d3 Drugs 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 claims 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000011529 cardiovascular cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096575P | 2014-12-24 | 2014-12-24 | |
| US62/096,575 | 2014-12-24 | ||
| PCT/JP2015/006462 WO2016103722A1 (en) | 2014-12-24 | 2015-12-24 | Vitamin d3 derivatives and pharmaceutical use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170855A Division JP7108356B2 (ja) | 2014-12-24 | 2020-10-09 | ビタミンｄ３誘導体及びその薬学的用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502100A JP2018502100A (ja) | 2018-01-25 |
| JP2018502100A5 true JP2018502100A5 (enExample) | 2019-02-28 |
| JP6784963B2 JP6784963B2 (ja) | 2020-11-18 |
Family
ID=56149780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534365A Active JP6784963B2 (ja) | 2014-12-24 | 2015-12-24 | ビタミンｄ３誘導体及びその薬学的用途 |
| JP2020170855A Active JP7108356B2 (ja) | 2014-12-24 | 2020-10-09 | ビタミンｄ３誘導体及びその薬学的用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170855A Active JP7108356B2 (ja) | 2014-12-24 | 2020-10-09 | ビタミンｄ３誘導体及びその薬学的用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20180265463A1 (enExample) |
| EP (1) | EP3237377B1 (enExample) |
| JP (2) | JP6784963B2 (enExample) |
| WO (1) | WO2016103722A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107652302B (zh) * | 2016-07-25 | 2020-09-15 | 深圳迈瑞生物医疗电子股份有限公司 | 化合物、缀合物、试剂盒及其用途 |
| CN114126623A (zh) * | 2019-05-17 | 2022-03-01 | 宾夕法尼亚大学董事会 | 治疗肥胖和/或皮肤紊乱的方法和组合物 |
| EP3906228A4 (en) * | 2019-07-09 | 2023-02-15 | Fermenta Biotech Limited | IMPROVED, LOW-COST PROCESS FOR SYNTHESIS OF VITAMIN D3 AND ITS ANALOGUE OF CALCIUM DIOL FROM ERGOSTEROL |
| JP7866317B2 (ja) * | 2020-09-17 | 2026-05-27 | 学校法人帝京大学 | Ｓｒｅｂｐの阻害剤としてのｖｄｒサイレントビタミンｄ誘導体およびこの薬学的使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6064924A (ja) * | 1983-09-21 | 1985-04-13 | Sankyo Co Ltd | 抗ビタミンｄ剤 |
| CA1333616C (en) * | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| CN104220450B (zh) * | 2012-04-12 | 2016-07-06 | 弗吉尼亚联邦大学 | 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS) |
| CN103585632A (zh) * | 2013-11-19 | 2014-02-19 | 韩源平 | 胆汁酸螯合剂或/和维生素d在制备防治非酒精性脂肪性肝病药物中的应用 |
-
2015
- 2015-12-24 EP EP15872293.4A patent/EP3237377B1/en active Active
- 2015-12-24 JP JP2017534365A patent/JP6784963B2/ja active Active
- 2015-12-24 WO PCT/JP2015/006462 patent/WO2016103722A1/en not_active Ceased
- 2015-12-24 US US15/539,260 patent/US20180265463A1/en not_active Abandoned
-
2020
- 2020-10-09 JP JP2020170855A patent/JP7108356B2/ja active Active
-
2023
- 2023-03-03 US US18/117,358 patent/US20230278955A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
| CN109715626A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| ATE517882T1 (de) | Chinolinderivate | |
| JP2016516043A5 (enExample) | ||
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| TN2014000033A1 (fr) | Indazoles | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| UA115881C2 (uk) | Алкоксипіразоли як активатори розчинної гуанілатциклази | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
| MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
| JP2015522650A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| MX2016016538A (es) | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa. | |
| JP2016503797A5 (enExample) | ||
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| FI20115234A0 (fi) | Uusia pyridatsinoni- ja pyridoniyhdisteitä | |
| PH12014500405A1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
| AR084505A1 (es) | Derivados de 5-metil-1-(naftalen-2-il)-1h-pirazol | |
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α |